Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, single-dose study to compare pharmacokinetic characteristics and safety of FKB238 with those of Avastin in healthy male subjects (HMR code 14-009)

Next Previous
Trial Profile

A randomised, double-blind, single-dose study to compare pharmacokinetic characteristics and safety of FKB238 with those of Avastin in healthy male subjects (HMR code 14-009)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus First in man; Pharmacokinetics
  • Sponsors Fujifilm Kyowa Kirin Biologics

Most Recent Events

  • 01 Apr 2022 Results published in the International Journal of Clinical Pharmacology and Therapeutics
  • 02 Jun 2017 Status changed from recruiting to completed, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
  • 02 Jun 2017 Primary endpoint (Pharmacokinetic parameter: AUC0-t) has been met, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top